160969-00-6

Basic information

• Product Name: 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide
• Synonyms: 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide;1-(2-Bromo-ethoxy)-2-(2,2,2,trifluro ethoxy)benzene;Silodosin InterMediate;1-(2-BroMoethoxy)-2-(2,2,2-trifluoroethoxy)benzene
• CAS NO: 160969-00-6
• Molecular Formula: C₁₀H₁₀BrF₃O₂
• Molecular Weight: 299.085
• EINECS: 1312995-182-4
• Mol File: 160969-00-6.mol

Chemical Properties

• Boiling Point: 273.6 °C at 760 mmHg
• Flash Point: 148 °C
• Appearance: cream
• Density: 1.495
• Vapor Pressure: 0.00948mmHg at 25°C
• Refractive Index: 1.482
• CAS DataBase Reference: 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide(160969-00-6)
• EPA Substance Registry System: 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide(160969-00-6)

Safety Data

• Hazardous Substances Data: 160969-00-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide is used as a reagent in organic synthesis for the preparation of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, making it a valuable building block for the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide has potential applications in the design and development of new therapeutic agents. Its ability to interact with biological molecules makes it a promising candidate for the creation of pharmaceutical compounds with specific biological activities.
Used in Drug Design:
2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide can be used as a building block in drug design, where its unique structural features can be exploited to create novel pharmaceutical compounds with desired properties. Its reactivity allows for the formation of new chemical entities that can target specific biological pathways or receptors, potentially leading to the development of new drugs for various diseases.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl bromide is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its versatility in organic synthesis and potential for creating new therapeutic agents make it an important component in the development of innovative drugs.

InChI:InChI=1/C10H10BrF3O2/c11-5-6-15-8-3-1-2-4-9(8)16-7-10(12,13)14/h1-4H,5-7H2

Upstream product

• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 90-05-1 2-methoxy-phenol 
• 160968-99-0 2-O-(2,2,2-trifluoroethyl)catechol 
• 106-93-4 ethylene dibromide 
• 106854-74-4 2-methoxy-1-(2,2,2-trifluoroethoxy)benzene 

Downstream Products

• 1031281-18-1 (-)-2-Methoxy-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]benzenesulfonamide 
• 160970-54-7 silodosin 
• 459868-77-0 2,3-dihydro-1-[3-(phenylmethoxy)propyl]-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile 
• 175870-40-3 1-[3-(benzyloxy)propyl]-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)-phenoxy]ethyl}amino)propyl]indoline-7-carboxamide 
• 1374461-73-0 1-[3-(benzyloxy)propyl]-5-[(2R)-2-([(1R)-1-phenylethyl]{2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]indoline-7-carbonitrile 

Relevant articles and documents

Synthesis and pharmacological evaluation of novel silodosin-based arylsulfonamide derivatives as α1A/α1D-adrenergic receptor antagonist with potential uroselective profile

Benign prostatic hyperplasia (BPH) is the most common male clinical problem impacting the quality of life of older men. Clinical studies have indicated that the inhibition of α1A-/α1D adrenoceptors might offer effective therapy in lower urinary tract symptoms. Herein, a limited series of arylsulfonamide derivatives of (aryloxy)ethyl alicyclic amines was designed, synthesized, and biologically evaluated as potent α1-adrenoceptor antagonists with uroselective profile. Among them, compound 9 (3-chloro-2-fluoro-N-([1-(2-(2-(2,2,2-trifluoroethoxy)phenoxy]ethyl)piperidin-4-yl) methyl) benzenesulfonamide) behaved as an α1A-/α1D-adrenoceptor antagonist (Ki(α1) = 50 nM, EC50(α1A) = 0.8 nM, EC50(α1D) = 1.1 nM), displayed selectivity over α2-adrenoceptors (Ki(α2) = 858 nM), and a 5-fold functional preference over the α1B subtype. Compound 9 showed adequate metabolic stability in rat-liver microsome assay similar to the reference drug tamsulosin (Clint = 67 and 41 μL/min/mg, respectively). Compound 9 did not decrease systolic and diastolic blood pressure in normotensive anesthetized rats in the dose of 2 mg/kg, i.v. These data support development of uroselective agents in the group of arylsulfonamides of alicyclic amines with potential efficacy in the treatment of lower urinary tract symptoms associated to benign prostatic hyperplasia.

1,5,7-trisubstituted indoline compounds and salts thereof

Indoline compounds represented by the formula: STR1 wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.